{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Return to MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
  • Sign In
  • Home
  • Live
  • On-Demand
  • RSS/Grand Rounds
  • Non-Accredited
  • About
  • Contact Us
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

MD Anderson workforce members:  Select "MD ANDERSON LOGIN" and enter your MD Anderson email address and password.

Guests (all other than MD Anderson workforce members): Select "GUEST LOGIN" and enter your email address and password.

MD ANDERSON LOGIN
GUEST LOGIN
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Back to Login Provider Forgot Your Password?

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • AA
  • AAS
  • ADN
  • BA
  • BS
  • BSN
  • DDS
  • DMD
  • DMin
  • DNP
  • DO
  • DrPH
  • DVM
  • DVM,PhD
  • EdD
  • JD
  • MA
  • MBA
  • MBBS
  • MBBS,MD
  • MD
  • MD, MBA
  • MD, MPH
  • MD, PhD
  • MDiv
  • MEd
  • MHA
  • MPA
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • Other
  • PharmD
  • PharmD, PhD
  • PhD
  • PsyD
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

A Comprehensive Board Review in Hematology and Medical Oncology


LIVEHematologyMedical OncologySolid TumorsBoard Review
A Comprehensive Board Review in Hematology and Medical Oncology Banner

  • Overview
  • Faculty
  • Schedule
  • Brochure
Add to Calendar A Comprehensive Board Review in Hematology and Medical Oncology 9/25/2023 7:00:00 AM 9/30/2023 5:10:00 PM America/Chicago For More Details: https://mdanderson.cloud-cme.com/Hmobr2023 Description: The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment,... MD Anderson - Virtual false MM/DD/YYYY


Date & Location
Monday, September 25, 2023, 7:00 AM - Saturday, September 30, 2023, 5:10 PM, MD Anderson - Virtual

Target Audience
Specialties - Colon and Rectal Surgery, Gynecologic Oncology, Hematology, Medical Oncology, Neurological Surgery, Obstetrics and Gynecology, Thoracic Surgery, Urology
Professions - Genetic Counselor, Nurse - APRN, Pharmacist, Physician (MD or DO), Physician Associate, Student or Trainee

Credits
AMA PRA Category 1 Credits™ (50.50 hours), ABIM MOC Part 2 (50.50 hours), Non-Physician Attendance (50.50 hours)

Overview
The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.

Objectives
At the conclusion of this activity, learners will be able to:

  1. Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology.
  2. Utilize current standards of care for patients with cancer, blood disorders and malignancies.
  3. Demonstrate proficiency of knowledge in hematology and medical oncology.
  4. Incorporate recent advances in management of hematologic and oncologic patients.
  5. Define molecular determinants of cancer risk and apply this knowledge in practice.

Registration


A Virtual Live Streaming Course


The Comprehensive Board Review in Hematology and Medical Oncology will be virtual. This program will be presented only as a live streaming course. You will receive an email from the course platform to log in and access the live course online approximately 3 days before the conference.

COMPREHENSIVE PROGRAM MATERIAL AVAILABLE FOR NON-ATTENDEES

CME Credits and MOC Points are awarded only by attending the virtual course.


For more information to purchase course material click here. 


PLANNING COMMITTEE
MD Anderson Cancer Center
Sharon Giordano, MD, MPH, Co-Director
Tapan Kadia, MD, Co-Director
Shreyaskumar Patel, MD
Alessandra Ferrajoli, MD
Nishin Bhadka, MD
Felisha Estelle


Baylor College of Medicine
Martha Mims, MD, PhD, Co-Director

PRESENTATIONS
Course syllabus will not be printed. Presentations (slides) will be available online via the course platform and Canvas. The PowerPoint presentations will be posted online as PDFs prior to the conference. You will receive an invitation email with directives to log in Canvas.

  • The Full Conference and Hematology Session will begin at 7:30 am on Monday, September 25, 2023. The Hematology Session will adjourn at 4:30 pm on Wednesday, September 27, 2023. The full conference will adjourn at 5:10 pm on Saturday, September 30, 2023.
  • The Oncology Session will begin at 12:30 pm on Tuesday, September 26, 2023 and adjourn at 5:10 pm on Saturday, September 30, 2023.

Advanced registration is encouraged.  Please see the registration fees below.

*NOTE: The conference registration fee includes the tuition, access to course virtual platform with PDFs of the slides and Canvas - online web-based system with recorded videos.

The deadline for advanced registration is Monday, September 11, 2023.

Telephone registrations are not accepted.

We accept the following forms of payment:

  • Credit Cards (MasterCard, VISA, and American Express)
  • Check (payable through U.S. banks only)
  • Mail to: Continuing Professional Education – Unit 1781, The University of Texas MD Anderson Cancer Center, P.O. Box 301407, Houston, TX 77230-1407

Make check payable to:  The University of Texas MD Anderson Cancer Center

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form.

CONFERENCE REGISTRATION FEES

Before
August 26, 2023
Before
September 11, 2023
After
September 11, 2023
Full Conference - MDs, PhDs, DOs, PharmDs  $1,200.00 $1,300.00 $1,400.00
Full Conference - Residents/Fellows/MD Anderson Alumni*  $800.00 $900.00 $1,000.00
Full Conference - Advanced Practice Providers/Nurses/Advanced Practice Nurses*  $450.00
Full Conference - MD Anderson/Baylor Faculty/Staff  $500.00
Full Conference - MD Anderson/Baylor Clinical Fellows*  Exempt
Hematology Session - 3 days (Monday - Wednesday) - MDs, PhDs, DOs, PharmDs  $550.00 $600.00 $650.00
Hematology Session - 3 days (Monday - Wednesday) - Residents/Fellows/MD Anderson Alumni*  $350.00 $400.00  $450.00 
Oncology Session - 4 1/2 days (Tuesday PM - Saturday) - MDs, PhDs, DOs, PharmDs  $650.00 $700.00 $750.00
Oncology Session - 4 1/2 days (Tuesday PM - Saturday) - Residents/Fellows/MD Anderson Alumni*  $450.00 $500.00 $550.00
 * A letter of introduction from the program director or chairperson with registration form is required to claim this reduced fee.

REFUND/CANCELLATION POLICY
The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before Monday, September 11, 2023.  No refunds will be granted after that date.  The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.  For additional information, contact Continuing Professional Education at 713-792-2223 or toll free at 866-849-5866.

Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary.  Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.

In case of activity cancellation, the liability of Continuing Professional Education is limited to the registration fee.  Continuing Professional Education will refund the full registration fee.

Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

Please let us know what specific topics, issues, or questions you wish to see addressed or emphasized in this activity by emailing Continuing Professional Education at [email protected]. All responses will be forwarded to the Program Directors for consideration.

EVALUATION
An online course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

SPECIAL ASSISTANCE
Contact Felisha Estelle in Continuing Professional Education at 713-745-0083 or 1-866-531-MOBR (6627) if you have any ADA accommodation needs.

Accreditation

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 50.50 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 50.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

In order to receive MOC points, you must pass the post-test with a score of 70% or higher.

Participant completion data will be shared with and transmitted to the ACCME on the participant’s behalf. 


Additional Information

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 




The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.



Mitigation of Relevant Financial Relationships


The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information
Role in activity
Nature of Relationship(s) / Name of Ineligible Company(s)
Huifang Lu, MD, PhD
Professor
MD Anderson Cancer Center
CE Reviewer
Nothing to disclose
Sharon H. Giordano, MD, FASCO
Professor
The University of Texas MD Anderson Cancer Center
Co-Director
Nothing to disclose
Tapan Kadia, MD
Professor
The University of Texas MD Anderson Cancer Center
Co-Director, Faculty
Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Pfizer Inc.|Grant or research support-AbbVie Inc.|Grant or research support-Amgen Inc.|Grant or research support-Genentech, Inc.|Grant or research support-Ascentage|Grant or research support-Cellenkos (Relationship has ended)|Grant or research support-AstraZeneca US|Grant or research support-Astellas Scientific and Medical Affairs, Inc.|Paid consultant-AbbVie Inc.|Paid consultant-Genentech, Inc.|Grant or research support-Genfleet|Grant or research support-Sellas, Inc|Grant or research support-Delta Fly Pharma|Grant or research support-Jazz Pharmaceuticals|Paid consultant-Jazz Pharmaceuticals|Paid consultant-Novartis Pharmaceuticals Corporation|Paid consultant-Daiichi Sankyo, Inc.|Paid consultant-Agios Pharmaceuticals Inc.|Paid consultant-Pfizer Inc.
Martha Mims, MD, PhD
Professor and Section Chief, Hematology/Oncology
Baylor College of Medicine
Co-Director, Faculty
Stocks or stock options, excluding diversified mutual funds-Amgen Inc.|Stocks or stock options, excluding diversified mutual funds-Biogen Inc.|Other: conduct of clinical trials-Millennium Pharmaceuticals, Inc., The Takeda Oncology Company|Other: Conduct of clinical trials-Celgene Corporation|Other: Conduct of clinical trials-Incyte Corporation|Other: conduct of clinical trials-inovio (Relationship has ended)|Other: conduct of clinical trials-Aveo
Lynne V. Abruzzo, MD, PhD
Adjunct Professor of Pathology
The Ohio State University
Faculty
Nothing to disclose
Rodabe N. Amaria, MD
Associate Professor, Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Grant or research support-Obsidian|Grant or research support-OnKure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar (Relationship has ended)
Kenneth Bauer, MD, Physician
Professor
Beth Israel Deaconess Medical Center
Faculty
Nothing to disclose
Nancy Berliner, MD
Chief, Division of Hematology
Brigham and Women's Hospital
Faculty
Nothing to disclose
Abenaa Brewster, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Lisa Carey, MD
Deputy Director for Clinical Sciences
UNC-Lineberger Comprehensive Cancer Center
Faculty
Nothing to disclose
Bradley Carthon, MD, PhD, MD, PhD
Associate Professor
Emory Healthcare
Faculty
Advisor-Gilead Sciences, Inc. (Relationship has ended)|Advisor-Bristol-Myers Squibb Company|Grant or research support-AstraZeneca US|Grant or research support-Bristol-Myers Squibb Company|Advisor-Eisai, Inc. (Relationship has ended)
Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor
Associate Professor
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech, Inc.|Advisor-Genomic Health, Inc. (Relationship has ended)
Jorge Cortes, MD
Director
Georgia Cancer Center at Augusta University
Faculty
Advisor-Pfizer Inc.|Advisor-Novartis Pharmaceuticals Corporation|Grant or research support-Novartis Pharmaceuticals Corporation|Advisor-Millennium Pharmaceuticals, Inc., The Takeda Oncology Company (Relationship has ended)|Advisor-Sun Pharma|Grant or research support-Sun Pharma|Advisor-Takeda|Advisor-BioPath Holdings|Grant or research support-AbbVie Inc.|Grant or research support-Ascentage
Courtney D. Dinardo, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Faculty
Honoraria-AbbVie Inc.|Honoraria-Forma|Honoraria-Daiichi Sankyo, Inc.|Honoraria-Gilead Sciences, Inc. (Relationship has ended)|Honoraria-Genentech, Inc.|Honoraria-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Honoraria-Bristol-Myers Squibb Company|Honoraria-GlaxoSmithKline|Honoraria-Jazz Pharmaceuticals|Honoraria-Novartis Pharmaceuticals Corporation (Relationship has ended)|Honoraria-Servier Pharmaceuticals|Honoraria-Immunogen (Relationship has ended)
Megan Dupuis , MD, PhD
Assistant Professor
Vanderbilt University Medical Center
Faculty
Nothing to disclose
Christopher R. Flowers, MD, FASCO
Chair, Lymphoma/Myeloma, Division Head Ad Interim, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Beigene|Consulting Fee-BioAscend (Relationship has ended)|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Curio Sciences (Relationship has ended)|Consulting Fee-Denovo Biopharma |Consulting Fee-Epizyme, Inc.|Consulting Fee-Genentech, Inc.|Consulting Fee-Foresight Diagnostics|Stocks or stock options, excluding diversified mutual funds-Foresight Diagnostics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Foresight Diagnostics|Consulting Fee-Genmab (Relationship has ended)|Consulting Fee-MorphoSys AG |Consulting Fee-Janssen Biotech, Inc. (Relationship has ended)|Consulting Fee-Seattle Genetics, Inc. (Relationship has ended)
Ravin J. Garg, MD
Medical Doctor
Maryland Oncology Hematology/US Oncology and Assistant Professor of Oncology/Johns Hopkins Hospital
Faculty
Nothing to disclose
Carl Gay, MD, PhD
The University of Texas MD Anderson Cancer Center
Faculty
Advisor-Bristol-Myers Squibb Company (Relationship has ended)|Advisor-G1 Therapeutics (Relationship has ended)|Advisor-AstraZeneca US (Relationship has ended)|Advisor-Jazz Pharmaceuticals (Relationship has ended)|Grant or research support-AstraZeneca US|Speakers Bureau-AstraZeneca US (Relationship has ended)|Advisor-Monte Rosa (Relationship has ended)|Speakers Bureau-Beigene (Relationship has ended)
Timothy D. Gilligan, MD, FASCO, FACH
Associate Professor & Vice-Chair for Education
Cleveland Clinic Taussig Cancer Institute
Faculty
Nothing to disclose
Betty Hamilton, MD
Cleveland Clinic
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-Incyte Corporation|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Angiocrine|Advisor-Equilium (Relationship has ended)|Advisor-Nkarta |Consulting Fee-Syndax (Relationship has ended)|Consulting Fee-Kadmon
Nasser H. Hanna, MD
Professor of Medicine
Indiana University
Faculty
Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Genentech, Inc.
Matthew Heeney, MD
Associate Chief - Hematology
Boston Children's Hospital
Faculty
Consulting Fee-Pharmacosmos|Consulting Fee-Keros Therapeutics
Mimi Hu, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Lilly USA, LLC
Claudine Isaacs, MD, FRCPC
Professor
Georgetown
Faculty
Consulting Fee-Genentech, Inc.|Consulting Fee-Biotheranostics (Relationship has ended)|Consulting Fee-PUMA|Consulting Fee-Seattle Genetics, Inc.|Consulting Fee-AstraZeneca US|Consulting Fee-Novartis Pharmaceuticals Corporation|Consulting Fee-Pfizer Inc.|Consulting Fee-ION Solutions (Relationship has ended)|Consulting Fee-Gilead Sciences, Inc.|Royalties or Patent Beneficiary-Wolters Kluwer (UpToDate)|Royalties or Patent Beneficiary-McGraw Hill (Goodman and Gillman)
Eric Jonasch, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Aveo|Grant or research support-ProFoundBio|Grant or research support-AbbVie Inc.|Grant or research support-Telix|Grant or research support-Aveo|Grant or research support-Corvus|Consulting Fee-Aravive|Grant or research support-Arrowhead|Consulting Fee-Eisai, Inc.|Honoraria-Exelixis|Honoraria-Ipsen US|Honoraria-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Honoraria-Nikang|Grant or research support-Nikang|Honoraria-Takeda (Relationship has ended)|Honoraria-DAVA
Hagop M. Kantarjian, MD
Chair, Leukemia
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-AbbVie Inc.|Grant or research support-Amgen Inc.|Grant or research support-Pfizer Inc.|Grant or research support-Takeda|Consulting Fee-AbbVie Inc.|Consulting Fee-Amgen Inc.|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Pfizer Inc.|Consulting Fee-Takeda
Scott Kopetz, MD, PhD
Professor, GI Medical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Advisor-MolecularMatch|Stocks or stock options, excluding diversified mutual funds-MolecularMatch|Stocks or stock options, excluding diversified mutual funds-Iylon Precision Oncology|Stocks or stock options, excluding diversified mutual funds-Lutris Pharmaceuticals|Advisor-Lutris Pharmaceuticals|Advisor-Iylon Precision Oncology|Consulting Fee-Genentech, Inc.|Consulting Fee-EMD Serono Inc.|Consulting Fee-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Consulting Fee-Holy Stone|Consulting Fee-Novartis Pharmaceuticals Corporation|Consulting Fee-Lilly USA, LLC|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Boston Biomedical|Consulting Fee-AstraZeneca/MedImmune|Consulting Fee-Bayer HealthCare Pharmaceuticals, Inc.|Consulting Fee-Pierre Fabre|Consulting Fee-Redx Pharma|Consulting Fee-Ipsen US|Consulting Fee-Daiichi Sankyo, Inc.|Consulting Fee-Natera|Consulting Fee-HalioDx|Consulting Fee-Lutris|Consulting Fee-Jacobio|Consulting Fee-Pfizer Inc.|Consulting Fee-Repare|Consulting Fee-Inivata|Consulting Fee-GlaxoSmithKline|Consulting Fee-Jazz Pharmaceuticals|Consulting Fee-Iylon Precision Oncology|Consulting Fee-Xilis|Consulting Fee-AbbVie Inc.|Consulting Fee-Amal Therapeutics|Consulting Fee-Gilead Sciences, Inc.|Consulting Fee-Mirati Therapeutics|Consulting Fee-Flame Biosciences|Consulting Fee-Servier|Consulting Fee-Carina Biotechnology|Consulting Fee-Bicara Therapeutics|Consulting Fee-Endeavor BioMedicines|Consulting Fee-Numab Pharma|Consulting Fee-Johnson & Johnson (any division)|Grant or research support-Sanofi US|Grant or research support-Biocartis|Grant or research support-Guardant Health|Grant or research support-Array Bio-Pharma|Grant or research support-Genentech/Roche|Grant or research support-EMD Serono Inc.|Grant or research support-MedImmune|Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Amgen Inc.|Grant or research support-Lilly USA, LLC|Grant or research support-Daiichi Sankyo
Mark Lewis, MD
Intermountain Healthcare
Faculty
Speakers Bureau-AstraZeneca US|Speakers Bureau-Natera|Consulting Fee-Pfizer Inc. (Relationship has ended)|Consulting Fee-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)
Whitney Lewis, PharmD
Clinical Pharmacy Specialist
The University of Texas MD Anderson Cancer Center
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-Takeda (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eisai, Inc. (Relationship has ended)|Speakers Bureau-Bristol-Myers Squibb Company (Relationship has ended)
Jennifer K. Litton, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Honoraria-UpToDate|Grant or research support-Pfizer Inc. (Relationship has ended)|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Grant or research support-Zenith (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-EMD Serono Inc.|Grant or research support-GlaxoSmithKline (Relationship has ended)|Grant or research support-Genentech, Inc. (Relationship has ended)|Speakers Bureau-Clinical Care Options|Speakers Bureau-Medscape|Speakers Bureau-Physician's Education Resource|Speakers Bureau-Prime Oncology (Relationship has ended)|Speakers Bureau-Medpage|Speakers Bureau-WebMD|Royalties or Patent Beneficiary-Certis|Speakers Bureau-@tumorboardtues (Relationship has ended)
Alice Ma, MD
Professor of Medicine
University of North Carolina
Faculty
Honoraria-Baxter Healthcare Corporation (Relationship has ended)
Claire Mach, PharmD
Clinical Pharmacy Specialist
Harris Health System
Faculty
Nothing to disclose
Stephan Moll, MD
UNC Chapel Hill
Faculty
Honoraria-Diagnostica Stago (Relationship has ended)
Alison Moskowitz, MD
Memorial Sloan Kettering Cancer Center
Faculty
Paid consultant-Physicians' Education Resource (Relationship has ended)|Other: speaking-Takeda Pharmaceuticals (Relationship has ended)|Other: speaking-Academic Medical Education (Relationship has ended)|Other: speaking-Bio Ascend (Relationship has ended)|Other: speaking-Canadian Hematology Conference (Relationship has ended)|Other: speaking-Canadian Hematology Society (Relationship has ended)|Other: speaking-Harborside Press LLC (Relationship has ended)|Other: speaking-Medscape (Relationship has ended)|Other: speaking-Tessa Therapeutics (Relationship has ended)|Other: speaking-Seagen (Relationship has ended)|Other: speaking-New York Oncology Hematology (Relationship has ended)|Other: speaking-SOHO Brazil (Relationship has ended)|Other: advisory-Affimed (Relationship has ended)|Other: advisory-Janpix Limited (Relationship has ended)|Other: advisory-Seattle Genetics (Relationship has ended)|Other: advisory-Kyowa Hakko Kirin Pharma (Relationship has ended)
Loretta J. Nastoupil, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Bristol-Myers Squibb Company|Honoraria-Incyte Corporation|Honoraria-Regeneron Pharmaceuticals, Inc.|Grant or research support-Janssen Biotech, Inc.|Grant or research support-Genentech, Inc.|Grant or research support-Gilead Sciences, Inc.|Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Takeda|Honoraria-ADC Therapeutics (Relationship has ended)|Grant or research support-Genmab|Honoraria-MEI (Relationship has ended)|Honoraria-Atara (Relationship has ended)|Grant or research support-Epizyme, Inc.
Kerry O'Brien, MD
Medical Director Blood Bank
Beth Israel Deaconess Medical Center
Faculty
Nothing to disclose
Susan O'Brien, MD
Professor of Medicine
University of California Irvine
Faculty
Consulting Fee-AbbVie Inc.|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Pharmacyclics LLC|Consulting Fee-Pfizer Inc.|Consulting Fee-Johnson & Johnson (any division)|Consulting Fee-Janssen Biotech, Inc.|Consulting Fee-GlaxoSmithKline|Consulting Fee-Gilead Sciences, Inc.|Consulting Fee-Genentech, Inc.|Consulting Fee-Celgene Corporation|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-AstraZeneca US|Consulting Fee-Astellas Scientific and Medical Affairs, Inc.|Consulting Fee-Amgen Inc.|Consulting Fee-Alexion Pharmaceuticals, Inc.
Timothy Olson, MD, PhD
Medical Director, Blood and Marrow Transplant Program
Children's Hospital of Philadelphia
Faculty
Advisor-Vertex Pharmaceuticals (Relationship has ended)|Consulting Fee-bluebird bio
Antonio Omuro, MD
Stanford University
Faculty
Grant or research support-Arcus Biosciences|Consulting Fee-Ono Pharma USA, Inc (Relationship has ended)|Consulting Fee-Servier Pharmaceuticals (Relationship has ended)|Consulting Fee-Pyramid (Relationship has ended)|Consulting Fee-Curevac AG
Brian Primeaux, PharmD
Clinical Pharmacy Specialist
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
S. Vincent Rajkumar, MD
Professor of Medicine
Mayo Clinic
Faculty
Nothing to disclose
Raajit Rampal, MD, PhD
Associate Member
MSKCC
Faculty
Advisor-AbbVie Inc.|Advisor-Blueprint Medicines Corporation|Advisor-Bristol-Myers Squibb Company|Advisor-GlaxoSmithKline|Advisor-Incyte Corporation|Advisor-Karyopharm Therapeutics|Advisor-Servier Pharmaceuticals
A. Koneti Rao, MD
Lewis Katz School of Medicine
Faculty
Nothing to disclose
Jose Alejandro Rauh-Hain, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Schlesinger Group|Consulting Fee-Guidepoint
Patrick K Reville, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Alvin H. Schmaier, MD
Robert W. Kellermeyer Professor
CASE WESTERN RESERVE UNIVERSITY
Faculty
Grant or research support-Merck Sharp & Dohme Corp. (any division)
Samuel A. Shelburne III, MD, Fellow Infectious Diseases Society of America
Professor, Infectious Diseases
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Arlene O. Siefker-Radtke, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Speakers Bureau-Janssen Biotech, Inc.|Honoraria-Basilea|Honoraria-Nektar Therapeutics|Honoraria-Immunomedics|Honoraria-Mirati |Honoraria-Loxo|Honoraria-Janssen Biotech, Inc.|Honoraria-Merck Sharp & Dohme Corp. (any division)|Honoraria-Gilead Sciences, Inc.|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Janssen Biotech, Inc.|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Honoraria-AstraZeneca US|Honoraria-Genentech, Inc.|Honoraria-Bristol-Myers Squibb Company|Honoraria-Seattle Genetics, Inc.|Honoraria-Taiho Oncology, Inc.|Grant or research support-Basilea Pharmaceutica|Grant or research support-Millennium|Grant or research support-Nektar Therapeutics|Grant or research support-Mirati (Relationship has ended)|Honoraria-Bavarian Nordic|Honoraria-Ideeya Immunomedics|Honoraria-G1 Therapeutics
Gerald A Soff, MD
Chief, Classical Hematology Service
University of Miami Health System/Sylvester Comprehensive Cancer Center
Faculty
Grant or research support-Amgen Inc.|Consulting Fee-Johnson & Johnson (any division) (Relationship has ended)
Senthil Sukumar, MD
Baylor College of Medicine
Faculty
Honoraria-Sanofi Genzyme (Relationship has ended)
Shannon N. Westin, MD, MPH
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-AstraZeneca US|Consulting Fee-AstraZeneca US|Grant or research support-AvengeBio|Grant or research support-Bayer HealthCare Pharmaceuticals, Inc.|Consulting Fee-Caris (Relationship has ended)|Grant or research support-Clovis Oncology (Relationship has ended)|Consulting Fee-Clovis Oncology (Relationship has ended)|Consulting Fee-Eisai, Inc. (Relationship has ended)|Consulting Fee-EQRX (Relationship has ended)|Grant or research support-Genentech, Inc.|Consulting Fee-Genentech, Inc. (Relationship has ended)|Consulting Fee-ImmunoGen|Grant or research support-GlaxoSmithKline|Consulting Fee-GlaxoSmithKline|Grant or research support-Jazz Pharmaceuticals|Grant or research support-Bio-Path|Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Lilly USA, LLC (Relationship has ended)|Grant or research support-Novartis Pharmaceuticals Corporation|Consulting Fee-Mersana|Grant or research support-Mereo|Consulting Fee-Mereo (Relationship has ended)|Consulting Fee-NGM Bio|Consulting Fee-Nuvectis|Consulting Fee-Seattle Genetics, Inc. (Relationship has ended)|Consulting Fee-Verastem|Consulting Fee-Vincerx (Relationship has ended)|Grant or research support-Zentalis|Consulting Fee-Zentalis|Grant or research support-Zentalis|Consulting Fee-ZielBio
William N. William Jr., MD
Medical Oncologist
Hospital BP
Brazil
Faculty
Consulting Fee-AstraZeneca US|Consulting Fee-Amgen Inc.|Consulting Fee-Bayer HealthCare Pharmaceuticals, Inc.|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Janssen Biotech, Inc.|Consulting Fee-Lilly USA, LLC|Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Novartis Pharmaceuticals Corporation|Consulting Fee-Pfizer Inc.|Consulting Fee-Sanofi Genzyme|Consulting Fee-Genentech, Inc.
Robert A. Wolff, MD
Professor, GI Medical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Harry H. Yoon, MD
Associate Professor
Mayo Clinic
Faculty
Grant or research support-Bristol-Myers Squibb Company|Grant or research support-CARsgen Therapeutics|Grant or research support-Macrogenics|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Advisor-ALX Oncology|Advisor-AstraZeneca US|Advisor-BeiGene|Advisor-Bristol-Myers Squibb Company|Advisor-Macrogenics|Advisor-Merck Sharp & Dohme Corp. (any division)|Advisor-OncXerna|Advisor-Zymeworks|Advisor-Novartis Pharmaceuticals Corporation|Advisor-Astellas Scientific and Medical Affairs, Inc.|Advisor-Elevation Oncology (Relationship has ended)|Advisor-Amgen Inc.
Felisha Estelle, BBA
CE Activity Planner
The University of Texas MD Anderson Cancer Center
Faculty, Other Planning Committee Member
Nothing to disclose
Shreyaskumar Patel, MD
Professor - Sarcoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Faculty, Other Planning Committee Member
Consulting Fee-Daiichi Sankyo, Inc. (Relationship has ended)|Consulting Fee-GlaxoSmithKline (Relationship has ended)|Consulting Fee-Adaptimmune (Relationship has ended)|Consulting Fee-Rain Oncology (Relationship has ended)|Consulting Fee-Deciphera|Consulting Fee-BioAtla (Relationship has ended)
Nishin Bhadkamkar, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Other Planning Committee Member
Nothing to disclose
Alessandra Ferrajoli, MD
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Other Planning Committee Member
Nothing to disclose

Monday, September 25, 2023
Virtual On-line Registration Check-in
7:00AM - 7:15AM
Welcome and Introduction
7:15AM - 7:30AM
Martha Mims, MD, PhD
 
BENIGN HEMATOLOGY SESSION: General Topics/Red Cell Disorders/Platelets

Iron Deficiency and Hemochromatosis
7:30AM - 8:15AM
Matthew Heeney, MD
Hematopoietic Growth Factors
8:15AM - 9:00AM
Martha Mims, MD, PhD
Bone Marrow Failure
9:00AM - 9:45AM
Timothy Olson, MD, PhD
Break
9:45AM - 10:00AM
Leukopenia and Leukocytosis
10:00AM - 10:45AM
Nancy Berliner, MD
Issues in Transfusion Medicine
10:45AM - 11:45AM
Kerry O'Brien, MD
Q & A Panel Discussion
11:45AM - 12:00PM
Matthew Heeney, MD
Martha Mims, MD, PhD
Timothy Olson, MD, PhD
Nancy Berliner, MD
Kerry O'Brien, MD
Lunch
12:00PM - 12:30PM
 
BENIGN HEMATOLOGY SESSION: Coagulation/Platelets/Red Cell Disorders

Sickle Cell Anemias, Thalassemia, and Hemoglobinopathies
12:30PM - 1:15PM
Alice Ma, MD
Hemolytic Anemias
1:15PM - 2:00PM
Gerald A Soff, MD
Approach to Anemia
2:00PM - 2:30PM
Alice Ma, MD
Break
2:30PM - 2:45PM
Disorders of Platelet Function
2:45PM - 3:30PM
A. Koneti Rao, MD
Charles A. Koller, MD Lectureship Award - 2023 Recipient
3:30PM - 3:35PM
Alvin H. Schmaier, MD
Thrombocytopenias
3:35PM - 4:15PM
Alvin H. Schmaier, MD
Q & A Panel Discussion
4:15PM - 4:30PM
Alice Ma, MD
A. Koneti Rao, MD
Alvin H. Schmaier, MD
Gerald A Soff, MD
Adjourn
4:30PM - 4:30PM
Tuesday, September 26, 2023
 
BENIGN HEMATOLOGY SESSION: Platelet/Red Cell Disorders/Transfusion Medicine

Antithrombotic & Antiplatelet Therapy
7:30AM - 8:15AM
Alvin H. Schmaier, MD
Normal Coagulation
8:15AM - 9:00AM
Kenneth Bauer, MD, Physician
Break
9:00AM - 9:15AM
Coagulation Factor Deficiencies, Including von Willebrands Disease and Hemophilias
9:15AM - 10:00AM
Kenneth Bauer, MD, Physician
Hypercoagulable States
10:00AM - 11:00AM
Stephan Moll, MD
Q & A Panel Discussion
11:00AM - 11:15AM
Alvin H. Schmaier, MD
Kenneth Bauer, MD, Physician
Stephan Moll, MD
Benign Hematology Q & A Session
11:15AM - 12:00PM
Senthil Sukumar, MD
Lunch Break
12:00PM - 12:30PM
 
MALIGNANT HEMATOLOGY SESSION: Lymphoma/Myeloma

Classification of Lymphoma
12:30PM - 1:15PM
Lynne V. Abruzzo, MD, PhD
Aggressive Non-Hodgkin Lymphoma
1:15PM - 2:00PM
Christopher R. Flowers, MD, FASCO
Indolent Non-Hodgkin Lymphoma
2:00PM - 2:45PM
Loretta J. Nastoupil, MD
Break
2:45PM - 3:00PM
Hodgkin Lymphoma
3:00PM - 3:45PM
Alison Moskowitz, MD
Multiple Myeloma and Other Plasma Cell Dyscrasias
3:45PM - 4:45PM
S. Vincent Rajkumar, MD
Q & A Panel Discussion
4:45PM - 5:00PM
Lynne V. Abruzzo, MD, PhD
Loretta J. Nastoupil, MD
Christopher R. Flowers, MD, FASCO
Adjourn
5:00PM - 5:01PM
Wednesday, September 27, 2023
 
MALIGNANT HEMATOLOGY SESSION: Leukemia/MDS

Chronic Myeloid Leukemia
7:30AM - 8:15AM
Jorge Cortes, MD
Myelodysplastic Syndrome
8:15AM - 9:15AM
Tapan Kadia, MD
Acute Myeloid Leukemia
9:15AM - 10:00AM
Courtney D. Dinardo, MD
Break
10:00AM - 10:15AM
Acute Lymphoblastic Leukemia
10:15AM - 11:00AM
Hagop M. Kantarjian, MD
Q & A Panel Discussion
11:00AM - 11:15AM
Jorge Cortes, MD
Tapan Kadia, MD
Courtney D. Dinardo, MD
Hagop M. Kantarjian, MD
Malignant Hematology Q & A Session
11:15AM - 12:00PM
Patrick K Reville, MD
Lunch Break
12:00PM - 12:30PM
 
MALIGNANT HEMATOLOGY SESSION: MPN/CLL/SCT

Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
12:30PM - 1:15PM
Susan O'Brien, MD
Myeloproliferative Neoplasms
1:15PM - 2:15PM
Raajit Rampal, MD, PhD
Break
2:15PM - 2:30PM
Stem Cell Transplant Supportive Care
2:30PM - 3:30PM
Betty Hamilton, MD
Infectious Complications in Cancer Patients
3:30PM - 4:15PM
Samuel A. Shelburne III, MD, Fellow Infectious Diseases Society of America
Q & A Panel Discussion
4:15PM - 4:30PM
Susan O'Brien, MD
Raajit Rampal, MD, PhD
Betty Hamilton, MD
Samuel A. Shelburne III, MD, Fellow Infectious Diseases Society of America
Adjourn
4:30PM - 4:31PM
Thursday, September 28, 2023
 
SOLID TUMOR SESSION: Pharmacology/Genetic Risk Factors/Sarcoma

Pharmacology I: Chemotherapy
7:30AM - 8:30AM
Claire Mach, PharmD
Pharmacology II: Targeted Therapy (Alk, EGFR, VEGR, HER2, HH, mTOR, PARP)
8:30AM - 9:00AM
Whitney Lewis, PharmD
Break
9:00AM - 9:15AM
Pharmacology III: Targeted Therapy (CD20, CD30, CD33, Proteasome, BCR-ABL/KIT, FLT3, IDH1/2, CDK4/6, PI3K)
9:15AM - 9:45AM
Brian Primeaux, PharmD
Pharmacology IV: Immunotherapy
9:45AM - 10:05AM
Claire Mach, PharmD
Break
10:05AM - 10:15AM
Genetic Risk Factors
10:15AM - 11:00AM
Claudine Isaacs, MD, FRCPC
Sarcoma
11:00AM - 12:00PM
Shreyaskumar Patel, MD
Q & A Panel Discussion
12:00PM - 12:15PM
Claire Mach, PharmD
Whitney Lewis, PharmD
Brian Primeaux, PharmD
Claudine Isaacs, MD, FRCPC
Shreyaskumar Patel, MD
Lunch
12:15PM - 12:45PM
 
SOLID TUMOR SESSION: Breast Cancer

Screening/Local Management of Breast Cancer
12:45PM - 1:30PM
Abenaa Brewster, MD
Systemic Treatment of Primary Breast Cancer Including HER2 Positive Breast Disease
1:30PM - 2:30PM
Lisa Carey, MD
Break
2:30PM - 2:45PM
Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Disease
2:45PM - 3:45PM
Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor
Special Issues in Breast Cancer
3:45PM - 4:15PM
Jennifer K. Litton, MD
Q & A Panel Discussion
4:15PM - 4:30PM
Abenaa Brewster, MD
Lisa Carey, MD
Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor
Jennifer K. Litton, MD
Solid Tumor Q & A - Session 1: Pharmacology/ Genetic Risk Factors/Sarcoma/Breast
4:30PM - 5:10PM
Mark Lewis, MD
Adjourn
5:10PM - 5:11PM
Friday, September 29, 2023
 
SOLID TUMOR SESSION: Lung Cancer/Head and Neck Cancer/Thyroid Cancer

Early Stage and Locally Advanced Non-Small Cell Lung Cancer
7:30AM - 8:15AM
Nasser H. Hanna, MD
Metastatic Non-Small Cell Lung Cancer
8:15AM - 9:15AM
Nasser H. Hanna, MD
Small Cell Lung Cancer
9:15AM - 9:45AM
Carl Gay, MD, PhD
Break
9:45AM - 10:00AM
Head and Neck Cancer
10:00AM - 10:45AM
William N. William Jr., MD
Thyroid Cancer
10:45AM - 11:15AM
Mimi Hu, MD
Q & A Panel Discussion
11:15AM - 11:30AM
Carl Gay, MD, PhD
William N. William Jr., MD
Mimi Hu, MD
Nasser H. Hanna, MD
ASH/ASCO Choosing Wisely Recommendations
11:30AM - 12:10PM
Ravin J. Garg, MD
Lunch Break
12:10PM - 12:45PM
 
SOLID TUMOR SESSION: Gastrointestinal Oncology

Pancreaticobiliary Cancers/Unknown Primary
12:45PM - 1:45PM
Robert A. Wolff, MD
Gastroesophageal Cancers/ Hepatocellular Carcinoma
1:45PM - 2:45PM
Harry H. Yoon, MD
Break
2:45PM - 3:00PM
Colorectal Cancer: Biology and Adjuvant Therapy
3:00PM - 3:30PM
Scott Kopetz, MD, PhD
Metastatic Colorectal Cancer and Anal Cancer
3:30PM - 4:30PM
Scott Kopetz, MD, PhD
Q & A Panel Discussion
4:30PM - 4:45PM
Robert A. Wolff, MD
Harry H. Yoon, MD
Scott Kopetz, MD, PhD
Solid Tumor Q & A - Session 2: Lung Cancer/ Head and Neck Cancer/Thyroid Cancer/ GI
4:45PM - 5:10PM
Megan Dupuis , MD, PhD
Adjourn
5:10PM - 5:11PM
Saturday, September 30, 2023
 
SOLID TUMOR SESSION: Genitourinary Oncology/Melanoma

Testicular Cancer
7:30AM - 8:30AM
Timothy D. Gilligan, MD, FASCO, FACH
Urothelial Cancer
8:30AM - 9:15AM
Arlene O. Siefker-Radtke, MD
Renal Cell Carcinoma
9:15AM - 10:00AM
Eric Jonasch, MD
Break
10:00AM - 10:15AM
Prostate Cancer
10:15AM - 11:15AM
Bradley Carthon, MD, PhD, MD, PhD
Melanoma
11:15AM - 12:00PM
Rodabe N. Amaria, MD
Q & A Panel Discussion
12:00PM - 12:15PM
Timothy D. Gilligan, MD, FASCO, FACH
Arlene O. Siefker-Radtke, MD
Eric Jonasch, MD
Rodabe N. Amaria, MD
Bradley Carthon, MD, PhD, MD, PhD
Lunch
12:15PM - 1:00PM
 
SOLID TUMOR SESSION: Neuro-Onc/Gynecologic Oncology

Neuro-Oncology
1:00PM - 1:45PM
Antonio Omuro, MD
Cervical Cancer
1:45PM - 2:30PM
Jose Alejandro Rauh-Hain, MD
Break
2:30PM - 2:45PM
Uterine Cancer
2:45PM - 3:15PM
Shannon N. Westin, MD, MPH
Ovarian Cancer and Unusual Ovarian Histologies
3:15PM - 4:15PM
Shannon N. Westin, MD, MPH
Q & A Panel Discussion
4:15PM - 4:30PM
Antonio Omuro, MD
Jose Alejandro Rauh-Hain, MD
Shannon N. Westin, MD, MPH
Solid Tumor Q & A – Session 3: Genitourinary/ Melanoma/Neuro-Oncology/Gyn Onc
4:30PM - 5:10PM
Ravin J. Garg, MD
Adjourn
5:10PM - 5:16PM

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
 Privacy policies   

©2023 The University of Texas MD Anderson Cancer Center
Contact Us: [email protected]

See us on Facebook See us on Twitter See us on Linked In See us on Instagram